The FDA Neurological Devices Panel said that Duraseal should be approved to prevent spinal fluid leakage during surgery. The product is already approved for use during brain surgery, according to the report.
FDA’s advisers attached several conditions to their endorsement, including a postmarket study to track safety issues for up to 90 days after surgery and said that the product’s labeling should mention that the long-term leakage rate for the device was about the same as surgical stitches, the current standard treatment, according to the repot.
Read about the FDA panel’s recommendation for Duraseal.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
